A randomized, double blind, double-dummy placebo controlled, 3-way cross-over study to determine the test-retest reliability of, and the effect of oral retigabine and riluzole on, peripheral motor nerve excitability measurements in patients with Amyotrophic-lateral-sclerosis.

Trial Profile

A randomized, double blind, double-dummy placebo controlled, 3-way cross-over study to determine the test-retest reliability of, and the effect of oral retigabine and riluzole on, peripheral motor nerve excitability measurements in patients with Amyotrophic-lateral-sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2017

At a glance

  • Drugs Retigabine (Primary) ; Riluzole
  • Indications Amyotrophic lateral sclerosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 26 Apr 2017 Status changed from recruiting to completed.
    • 12 Dec 2015 Planned number of patients changed from 16 to 18 as reported by European Clinical Trials Database record.
    • 01 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top